News

Published on 21 Jun 2022 on MarketWatch

Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote


Article preview image

Shares of Acadia Pharmaceuticals Inc. were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the company's treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The committee on Friday voted 9-3 that the benefits of pimavanserin do not outweigh the risks. The FDA, which is not required to follow the advice of the committee but often does, is expected to decide whether to approve the therapy by Aug. 4. "It's unlikely that the FDA will grant approval to Acadia's [supplemental new drug application] for ADP, and the agency will likely reiterate its original request for another study," Mizuho Securities analyst Vamil Divan told investors on Friday. The therapy is already approved as a treatment for hallucinations and delusions associated with Parkinson's disease psychosis. Acadia's stock is down 16.4% this year, while the S&P 500 has declined 22.9%.

NASDAQ.ACAD price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Is Acadia Pharmaceuticals Stock Trading Lower On Tuesday? - ACADIA Pharmaceuticals (NASDAQ:ACAD)

Monday, Acadia Pharmaceuticals Inc ACAD released top-line results from the Phase 3 ADVANCE-2 tria...

Benzinga 12 Mar 2024

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

Acadia Pharmaceuticals Inc. ACAD shares lost 15% in the after-market hours on Mar 11, after the c...

Zacks via Yahoo Finance 12 Mar 2024

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday’s...

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points o...

Benzinga 12 Mar 2024

Acadia Pharma’s stock falls 15% after failed drug trial

Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after ...

Market Watch 11 Mar 2024

Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Yearly...

Shareholders might have noticed that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) filed its annual r...

Simply Wall St. via Yahoo Finance 1 Mar 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2023 Earnings Call Transcript February 27, 2024 ACAD...

Insider Monkey via Yahoo Finance 29 Feb 2024

Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2023 earnings of 28 cents per share, mis...

Zacks via Yahoo Finance 28 Feb 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even

We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business...

Simply Wall St. via Yahoo Finance 25 Feb 2024

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares

On January 8, 2024, CEO Stephen Davis sold 3,732 shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACA...

GuruFocus.com via Yahoo Finance 14 Jan 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Fly 25% But Investors Aren't Buying For Growth

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders would be excited to see that the share pri...

Simply Wall St. via Yahoo Finance 18 Dec 2023